Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Evoke Pharma, Inc.    EVOK

EVOKE PHARMA, INC.

(EVOK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
2.62(c) 2.71(c) 2.73(c) 2.91(c) 2.78(c) Last
181 721 222 416 2 596 037 2 059 256 920 380 Volume
+1.95% +3.44% +0.74% +6.59% -4.47% Change
More quotes
Financials (USD)
Sales 2020 0,85 M - -
Net income 2020 -13,8 M - -
Net Debt 2020 - - -
P/E ratio 2020 -5,20x
Yield 2020 -
Sales 2021 14,8 M - -
Net income 2021 0,43 M - -
Net Debt 2021 - - -
P/E ratio 2021 111x
Yield 2021 -
Capitalization 87,3 M 87,3 M -
Capi. / Sales 2020 103x
Capi. / Sales 2021 5,89x
Nbr of Employees 5
Free-Float 80,9%
More Financials
Company
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic... 
Sector
Pharmaceuticals
Calendar
03/10Earnings Release
More about the company
All news about EVOKE PHARMA, INC.
01/14EVOKE PHARMA INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/14EVOKE PHARMA : Announces Positive Findings from GIMOTI Market Research Study
AQ
01/14EVOKE PHARMA : Prices $12.5 Million Public Offering
MT
01/13Evoke Pharma Announces Pricing of Public Offering of Common Stock
GL
01/13EVOKE PHARMA : Proposes Public Stock Sale; Shares Drop Almost 7% After Hours
MT
01/13EVOKE PHARMA INC : Results of Operations and Financial Condition, Other Events (..
AQ
01/13Evoke Pharma Announces Proposed Public Offering of Common Stock
GL
01/13EVOKE PHARMA : Rises 8% on Positive Findings from Market Study for Diabetic Gast..
MT
01/13Evoke Pharma Announces Positive Findings from GIMOTI™ Market Research S..
GL
2020EVOKE PHARMA INC : Entry into a Material Definitive Agreement, Termination of a ..
AQ
2020EVOKE PHARMA : Files for Up to $100 Million Mixed Shelf
MT
2020INSIDER TRENDS : Evoke Pharma Insider Disposes Company Shares, 90-Day Trend Neut..
MT
2020INSIDER TRENDS : Evoke Pharma Insider Disposition Interrupting 90-Day Buy Trend
MT
2020EVOKE PHARMA : Reports Third Quarter 2020 Financial Results
AQ
2020EVOKE PHARMA : Management's Discussion and Analysis of Financial Condition and R..
AQ
More news
News in other languages on EVOKE PHARMA, INC.

- No features available -

More news
Chart EVOKE PHARMA, INC.
Duration : Period :
Evoke Pharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOKE PHARMA, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 9,50 $
Last Close Price 2,78 $
Spread / Highest target 260%
Spread / Average Target 242%
Spread / Lowest Target 224%
EPS Revisions
Managers and Directors
NameTitle
David A. Gonyer President, Chief Executive Officer & Director
Cam L. Garner Chairman
Marilyn R. Carlson Chief Medical Officer
Todd C. Brady Independent Director
Malcolm R. Hill Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
EVOKE PHARMA, INC.7.75%87
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG2.48%305 385
NOVARTIS AG1.97%218 041
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.30%203 993